Tvardi Therapeutics Q3 net loss widens slightly less than expected
TVRD•Tvardi Therapeutics reported a third-quarter net loss of $6.1 million, slightly below the $6.19 million analyst estimate. The company expects existing cash to fund operations into Q3 2027 and plans clinical milestones that year, subject to conditions.
1. Quarterly results
Tvardi Therapeutics' third-quarter net loss widened year over year to $6.1 million, slightly below analysts' $6.19 million estimate. Loss per share was $0.48.
2. Clinical plans and cash
Research and development expenses rose primarily because of higher clinical costs for TTI-101, while general and administrative expenses decreased mainly due to lower professional fees. Tvardi expects existing cash to fund operations as planned into Q3 2027. It expects topline data from its TTI-101 liver cancer study in early Q1 2027 and plans to start a TTI-109 ulcerative colitis trial in 2027, pending IND clearance and additional funding.
